Cancer immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit.
It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or …

Cancer vaccines have undergone a renaissance because of recent clinical trials showing
promising immunologic data and some clinical benefit to patients. Current trials exploiting …

Dendritic cells (DCs) are the most powerful professional antigen-presenting cells and are
unique in their capability to initiate, maintain and regulate the intensity of primary immune …

Dendritic cells (DCs) occupy a central position in the immune system, orchestrating a wide
repertoire of responses that span from the development of self-tolerance to the elicitation of …

According to the GLOBOCAN reports, there were about 12.7 million cancer cases and 7.6
million cancer deaths in 2008, and the cancer burden continues to increase worldwide [1]. At …

Dendritic cells (DCs) are believed to be the most potent antigen-presenting cells able to link
the innate and adaptive immune systems. Many studies have focused on different …

Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in
animal models and humans have led to their exploitation as anticancer vaccines. Although …

The discovery that dendritic cells (DC) play a key role in regulating antitumor immunity has
prompted considerable efforts in developing DC-based cancer vaccines for use in clinical …

Therapeutic cancer vaccines rely on the immune system to eliminate tumor cells. In contrast
to chemotherapy or passive (adoptive) immunotherapies with antibodies or ex vivo …

Dendritic cells (DCs) are the most potent professional antigen-presenting cells of the
immune system. They acquire and process antigen and migrate to the lymphoid organs …